(Sharecast News) - The Covid19 vaccine being trialled by AstraZeneca and the University of Oxford was likely not behind the symptoms of one participant which led to the pause in the phase three trials last week, documents provided to the volunteers show.
According to the participant information sheet posted online by Oxford, an independent review concluded that the illnesses were either "unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine."
"In each of these cases, after considering the information, the independent reviewers recommended that vaccinations should continue."
The trial was halted on 9 September after one of the participants developed neurological symptoms, the second such instance from among all the volunteers.
Nevertheless, the independent panel overseeing the trials judged that the symptoms were unrelated to the vaccine.
A read out from the trials is expected in October and according to AstraZeneca boss, Pascal Soriot, the vaccine may yet be available by the end of 2020.
Related trials of the vaccine candidate have since restarted in South Africa and India, but not yet in the US.
Astrazeneca (AZN)Today 10:04
AstraZeneca notes positive trial results for Calquence treatment
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
